Contezolid-Containing Regimen Successfully Treated Multiple Drug Resistance Mycobacterium Abscessus Complex Infection of Skin: A Case Report and Literature Review
DOI: https://doi.org/10.2147/idr.s453541
2024-03-28
Infection and Drug Resistance
Abstract:Xusheng Gao, Caihong Ding, Dan Xie, Qing Wang, Peipei Jiang, Yuyu Wang, Yu Xiong Department of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People's Republic of China Correspondence: Yu Xiong, Department of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, No. 11, Lieshishan East Road, Licheng District, Jinan, Shandong, People's Republic of China, Tel +8615589995880, Email Background: In recent decades, there has been a substantial surge in the incidence of non-tuberculous Mycobacteria (NTM) infections. However, the diagnosis and management of NTM globally present significant challenges, particularly in cases involving Mycobacterium abscessus complex (MABC) infection where effective therapeutic options are limited. Case Presentation: We reported a 38-year-old female patient who was infected with MABC of skin due to "beauty needle" at a beauty salon, with mass on both cheeks, accompanied by redness, and pain, and some of them was ulcered and effused. Puncture pumping pus from bilateral cheek mass for many times, rinsed with "metronidazole", and oral "cephalosporin" treatment did not work. Therefore, she came to our hospital. MABC was detected in abscess paracentesis pus by nucleic acid mass spectrometry, and was proved by the cultured result of the pus. Thus, the patient was diagnosed as skin MABC infection, and anti-NTM treatment was taken. However, adverse reactions such as tinnitus, hepatotoxicity and neurovirulence occurred during the initial treatment. After adjusting to the contezolid-containing regimen, these adverse reactions improved. After nearly 6 months of treatment, the cheek mass was gradually reduced and the skin ruptures were gradually healed. Follow-up for 10 months showed that the patient's facial symptoms were significantly improved, and no drug-related adverse reactions happened. Conclusion: This was the first successful case of multiple drug resistance MABC infection of skin treated with contezolid-containing antibiotic management strategies, which exhibited remarkable efficacy and good safety in this intractable disease. Keywords: Mycobacterium abscessus complex , antibiotic therapy, contezolid, Case report Non-Tuberculous Mycobacteria (NTM), represents a diverse group of mycobacteria distinct from the Mycobacterium tuberculosis complex and the Mycobacterium leprae. Over the past few decades, the incidence of NTM infections has significantly risen due to factors such as population aging and an increase in immunocompromised individuals. This surge has established NTM as a prominent public health concern. 1–4 Presently, more than 190 species and subspecies of NTM have been identified, with dozens capable of causing diseases in humans. Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABC) contribute to 70% to 95% of NTM infections. 5 Skin infections, especially fast-growing mycobacteria, frequently manifest as non-healing ulcers, subcutaneous abscesses, draining sinuses, or indurated nodules. The histopathological presentation varies depending on the evolution of the disease and the immune status of the host. 6 MABC exhibits inherent resistance to most first-line anti-tubercular drugs, displaying susceptibility only to a limited range of antibiotics and demonstrating a propensity for rapid development of resistance. Coupled with extended disease courses, high rates of recurrence, medication-related adverse effects, and drug-drug interactions, treatment success rates for MABC-related diseases are disappointingly low, typically ranging from 50% to 66%, resulting in elevated mortality rates. This situation poses considerable challenges to anti-infective therapy. 7–9 Both domestic and international guidelines 5,10,11 provide recommendations for NTM treatment that for the treatment of MABC skin and soft tissue infections, therapeutic approaches involving amikacin (AMK), cefoxitin (CFX), clarithromycin (CLA), or azithromycin are suggested. In cases of resistance to CLA or azithromycin, treatment options encompass linezolid or Minocycline (MINO).However, the formulation of guideline-based treatment plans for NTM, especially MABC patients, is fraught with challenges. These include the high cost of medications, limited accessibility, and the relatively elevated occurrence of adverse effects associated with amikacin. Therefore, there is an urgent need for research into antimicrobial therapy options for MABC-induced infectious diseases. Contezolid, a kind of novel and potent antibiotics, is classified as an oxazolidinone antibiotic with a primary spectrum targeting aerobic Gram-positive bacteria. It's structurally derived from linezolid and demonstrates anti -Abstract Truncated-
pharmacology & pharmacy,infectious diseases